Bausch Health Americas, Inc.
Clinical trials sponsored by Bausch Health Americas, Inc., explained in plain language.
A subsidiary of Bausch Health, focused on pharmaceuticals and medical devices in the Americas.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for kids with colitis: budesonide pill trial aims for remission Results expected Dec 2026 (estimated)
- New radiofrequency treatment aims to tighten sagging skin without surgery Results expected Feb 2027 (estimated)
- New hope for Kids' diarrhea: drug plus fluids tested Results expected Apr 2027 (estimated)
-
Can this IV drug help avoid liver transplants in heavy drinkers?
Disease control Recruiting nowThis Phase 3 trial tests an experimental drug called larsucosterol in 350 people with severe alcohol-associated hepatitis. The goal is to see if the drug helps patients survive for 90 days without needing a liver transplant. Participants receive either the drug or a placebo by IV…
Phase 3 • Sponsor: Bausch Health Americas, Inc. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New hope for Kids' diarrhea: drug plus fluids tested
Disease control Recruiting nowThis study tests how the drug rifaximin (Xifaxan) works in children aged 6 to 11 with acute diarrhea likely caused by bacteria. Half the children get the drug plus oral rehydration therapy, the other half get rehydration alone. Researchers want to see if adding the drug helps dia…
Phase 4 • Sponsor: Bausch Health Americas, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New acne gel studied for younger kids: could it clear up moderate to severe breakouts?
Disease control Recruiting nowThis study is testing a gel called CABTREO, which combines three acne-fighting ingredients (clindamycin, adapalene, and benzoyl peroxide), in children aged 9 to 11 with moderate to severe acne. The goal is to see if it is safe and works well over 12 weeks. About 100 kids will app…
Phase 4 • Sponsor: Bausch Health Americas, Inc. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New hope for kids with colitis: budesonide pill trial aims for remission
Disease control Recruiting nowThis study tests whether budesonide extended-release tablets can safely help children aged 5 to 17 with mild to moderate ulcerative colitis achieve remission. About 70 participants will receive either a low dose, high dose, or placebo for 56 days. The goal is to reduce symptoms l…
Phase 4 • Sponsor: Bausch Health Americas, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:32 UTC
-
New radiofrequency treatment aims to tighten sagging skin without surgery
Symptom relief Recruiting nowThis study is testing a device called Thermage FLX that uses radiofrequency energy to improve wrinkles and tighten loose skin on the neck, abdomen, upper arms, and face. About 164 adults with mild-to-moderate skin laxity or wrinkles will receive the treatment and be followed for …
Sponsor: Bausch Health Americas, Inc. • Aim: Symptom relief
Last updated Aug 28, 2026 00:00 UTC